4811
T3D4756
Triamcinolone
A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated.
124-94-7
31307
C21H27FO6
White powder.
270°C
80 mg/L (at 25°C)
Rapid absorption following oral administration
The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Hepatic.
Half Life: 88 minutes
LD<sub>50</sub>=>500mg/kg (in rats)
No indication of carcinogenicity to humans (not listed by IARC).
For the treatment of perennial and seasonal allergic rhinitis.
2014-09-11T05:15:03Z
2026-03-27T01:56:19Z
Triamcinolone
481691
DB00620
true
[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
C21H27FO6
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
GFNANZIMVAIWHM-OBYCQNJPSA-N
394.4339
394.179166801
Exogenous
Solid
1.16
HMDB14758
CHEMBL1451
29046
<p>Abu Alam, “Triamcinolone formulations and methods for their preparation and use.” U.S. Patent US20040186084, issued September 23, 2004.</p>
CHEM003713
DTXSID1040742
NS00007956
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one